It is worth investigating whether the addition of dual anti-HER2 therapy to total neoadjuvant therapy could potentially augment the pCR rate in rectal cancer patients with HER2 amplification, or if these patients can be spared from radiotherapy within this treatment regimen without compromising efficacy. Here, ERBB2 is linked to rectal cancer.